Randomized, controlled trial of transdermal clonidine for smoking cessation

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

OBJECTIVE: To determine the efficacy and safety of clonidine versus placebo in smoking cessation. DESIGN: Single-center, randomized, double-blind, parallel-design comparison of transdermal clonidine with behavior modification, transdermal clonidine without behavior modification, placebo with behavior modification, and placebo without behavior modification. SETTING: Outpatient, university-based ambulatory care facility. PATIENTS: One hundred fifty generally healthy, highly nicotine-dependent cigarette smokers. INTERVENTION: Clonidine was given as the transdermal patch initiated 72 hours prior to smoking-cessation attempts and continued for six weeks thereafter. Clonidine was given at a dose of 0.2 mg/d for patients weighing more than 150 pounds (>67.5 kg) and at a dose of 0.1 mg/d for patients weighing less than 150 pounds (

Original languageEnglish
Pages (from-to)1025-1028
Number of pages4
JournalAnnals of Pharmacotherapy
Volume27
Issue number9
DOIs
StatePublished - 1993

Fingerprint

Clonidine
Smoking Cessation
Behavior Therapy
Randomized Controlled Trials
Placebos
Transdermal Patch
Ambulatory Care Facilities
Nicotine
Tobacco Products
Outpatients
Safety

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Randomized, controlled trial of transdermal clonidine for smoking cessation. / Hilleman, Daniel E.; Mohiuddin, Syed M.; Del Core, Michael; Lucas, B. Daniel.

In: Annals of Pharmacotherapy, Vol. 27, No. 9, 1993, p. 1025-1028.

Research output: Contribution to journalArticle

@article{826c54231e434c3c98fa6f43e83d0563,
title = "Randomized, controlled trial of transdermal clonidine for smoking cessation",
abstract = "OBJECTIVE: To determine the efficacy and safety of clonidine versus placebo in smoking cessation. DESIGN: Single-center, randomized, double-blind, parallel-design comparison of transdermal clonidine with behavior modification, transdermal clonidine without behavior modification, placebo with behavior modification, and placebo without behavior modification. SETTING: Outpatient, university-based ambulatory care facility. PATIENTS: One hundred fifty generally healthy, highly nicotine-dependent cigarette smokers. INTERVENTION: Clonidine was given as the transdermal patch initiated 72 hours prior to smoking-cessation attempts and continued for six weeks thereafter. Clonidine was given at a dose of 0.2 mg/d for patients weighing more than 150 pounds (>67.5 kg) and at a dose of 0.1 mg/d for patients weighing less than 150 pounds (",
author = "Hilleman, {Daniel E.} and Mohiuddin, {Syed M.} and {Del Core}, Michael and Lucas, {B. Daniel}",
year = "1993",
doi = "10.1177/106002809302700901",
language = "English",
volume = "27",
pages = "1025--1028",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "9",

}

TY - JOUR

T1 - Randomized, controlled trial of transdermal clonidine for smoking cessation

AU - Hilleman, Daniel E.

AU - Mohiuddin, Syed M.

AU - Del Core, Michael

AU - Lucas, B. Daniel

PY - 1993

Y1 - 1993

N2 - OBJECTIVE: To determine the efficacy and safety of clonidine versus placebo in smoking cessation. DESIGN: Single-center, randomized, double-blind, parallel-design comparison of transdermal clonidine with behavior modification, transdermal clonidine without behavior modification, placebo with behavior modification, and placebo without behavior modification. SETTING: Outpatient, university-based ambulatory care facility. PATIENTS: One hundred fifty generally healthy, highly nicotine-dependent cigarette smokers. INTERVENTION: Clonidine was given as the transdermal patch initiated 72 hours prior to smoking-cessation attempts and continued for six weeks thereafter. Clonidine was given at a dose of 0.2 mg/d for patients weighing more than 150 pounds (>67.5 kg) and at a dose of 0.1 mg/d for patients weighing less than 150 pounds (

AB - OBJECTIVE: To determine the efficacy and safety of clonidine versus placebo in smoking cessation. DESIGN: Single-center, randomized, double-blind, parallel-design comparison of transdermal clonidine with behavior modification, transdermal clonidine without behavior modification, placebo with behavior modification, and placebo without behavior modification. SETTING: Outpatient, university-based ambulatory care facility. PATIENTS: One hundred fifty generally healthy, highly nicotine-dependent cigarette smokers. INTERVENTION: Clonidine was given as the transdermal patch initiated 72 hours prior to smoking-cessation attempts and continued for six weeks thereafter. Clonidine was given at a dose of 0.2 mg/d for patients weighing more than 150 pounds (>67.5 kg) and at a dose of 0.1 mg/d for patients weighing less than 150 pounds (

UR - http://www.scopus.com/inward/record.url?scp=0027429314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027429314&partnerID=8YFLogxK

U2 - 10.1177/106002809302700901

DO - 10.1177/106002809302700901

M3 - Article

VL - 27

SP - 1025

EP - 1028

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 9

ER -